All Articles

NGS Testing More Cost-Effective Than SGT in Oncology

Analysis of the long-term results of the CodeBreak 100 clinical trial showed that sotorasib demonstrated long-term efficacy, in particular among patients with low initial circulating tumor DNA values.

Phase 3 Study of Sotorasib in NSCLC Demonstrated Shorter PFS Than Phase 1/2 Trials

A recent study showed that next-generation sequencing testing has superior cost benefit when compared with single-gene testing for multiple cancer types, including non–small cell lung cancer.

Discordance Found Between Liquid and Tissue Biopsies in NGS in Patients With Non–Small Cell Lung Cancer at Disease Progression

Analysis of the phase 3 study of sotorasib in patients with non–small cell lung cancer found faster time to response compared with docetaxel but a shorter progression-free survival than what was seen in the phase 1/2 trials.

National Nurses Month: Celebrating the Impact of Nurses

A recently released study found a significant concordance rate drop between liquid and tissue biopsies via next-generation sequencing when patients had disease progression.

By Lillie D. Shockney, RN, BS, MAS, HON-ONN-CG

Letters from Lillie

Nurse Navigators as the Drivers to an Enhanced Patient Referral Process

All day, every day, nurses make all the difference in delivering high-quality care to those who need it the most. On behalf of all of us at AONN+, I want to recognize the nurses in our community for their invaluable contributions to healthcare.

Original Research

The CATCH: In Support of Collaboration

Within the structure of a center-wide patient access redesign initiative, the nurse navigators evaluated their contributions and activities as professional registered nurses. They noticed a lack of standard interview questions and a patient referral process that holistically supported patients.

The CATCH

Our Health History Is in the Stories We Tell Within Black and Brown Families

One of Alessandra’s patients lives more than 100 miles from the cancer center in an isolated region with limited access to specialty cancer care. When a visit to the cancer center was necessary, the patient had a 2- to 4-hour commute, depending on the location of the scheduled treatment.

By Maimah Karmo

Patient Advocacy/Empowerment